Physician profile
Antonio Joseph
NPI 1467435271
$2,372.24
in general payments reported to CMS, 2019-2025
27 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $365 · 2021: $55.12 · 2022: $128 · 2023: $140 · 2024: $234 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682 · Education: $14.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.53 |
| Education | $14.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $673.84 | 2019-2025 | Rayaldee |
| Merck Sharp & Dohme LLC | $204.73 | 2019-2021 | |
| Lilly USA, LLC | $187.08 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $177.22 | 2019-2023 | Parsabiv, Tavneos |
| Novo Nordisk INC | $167.40 | 2019-2024 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $124.28 | 2019-2020 | |
| Gilead Sciences, INC. | $118.71 | 2025 | Livdelzi |
| Aurinia Pharma U.S., INC. | $73.76 | 2021-2024 | Lupkynis |
| Horizon Therapeutics Plc | $71.69 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $69.06 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $55.25 | 2019-2024 | Airsupra |
| Mallinckrodt Hospital Products INC. | $54.17 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.10 | 2019-2020 | |
| Travere Therapeutics, INC. | $46.14 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.61 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $34.17 | 2019 | |
| Akebia Therapeutics INC | $32.87 | 2019 | |
| Daiichi Sankyo INC. | $22.06 | 2019 | |
| Shire North American Group INC | $21.82 | 2019 | |
| Sanofi Pasteur INC. | $20.51 | 2019 | |
| Strongbridge US INC. | $19.76 | 2019 | |
| Amarin Pharma, INC. | $19.28 | 2019 | |
| Allergan, INC. | $19.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.56 | 2024 | |
| Abbott Laboratories | $15.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.34 | 2019 | |
| Seqirus USA INC | $15.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.